BellRing Brands (BRBR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jan, 2026Executive summary
Fiscal 2025 began with strong momentum, with Q1 net sales up 24% year-over-year to $532.9 million, driven by Premier Protein and Dymatize brands.
Net earnings rose 75% to $76.9 million, and operating profit increased 58% to $115.3 million, reflecting improved margins and lower costs.
Premier Protein achieved record household penetration and distribution, with RTD shakes and powder consumption up over 23%.
The business is focused on demand generation, leveraging expanded capacity, national advertising, and innovation.
Fiscal 2025 outlook was raised for both net sales and adjusted EBITDA, reflecting strong category momentum.
Financial highlights
Q1 net sales reached $533 million, up 24% year-over-year; adjusted EBITDA was $125 million, up 25%.
Gross profit grew 35% to $200 million, with gross margin up 310 bps to 37.5%.
Adjusted EBITDA margin was 23.5%, exceeding expectations due to favorable gross margins and marketing spend timing.
Diluted EPS was $0.59, up from $0.33 year-over-year; adjusted diluted EPS was $0.58, up from $0.43.
Cash from operations was $3 million, down from $74.2 million, mainly due to inventory build and timing of payables.
Outlook and guidance
Fiscal 2025 net sales guidance raised to $2.26–$2.34 billion (13–17% growth); adjusted EBITDA guidance raised to $470–$500 million (7–14% growth).
Adjusted EBITDA margins expected at 21.1% midpoint for the year, with stronger growth in the first half due to marketing and cost phasing.
Q2 net sales expected to grow mid-to-high teens, with Premier Protein as the main driver; Dymatize and others expected flat to down.
Capital expenditures for fiscal 2025 expected to be approximately $7 million.
The company expects to generate positive cash flows and maintain sufficient liquidity.
Latest events from BellRing Brands
- Strong 2025 sales and brand momentum, with 2026 guidance showing growth and margin pressure.BRBR
Q4 20259 Jul 2026 - Q2 net sales up 19% with Premier Protein driving record growth; FY2025 outlook reaffirmed.BRBR
Q2 20259 Jul 2026 - Premier Protein drove strong sales and EBITDA growth, with double-digit 2025 outlook despite margin pressures.BRBR
Q4 20248 Jul 2026 - Net sales up 1% to $537.3M, margins fell, 2026 outlook narrowed, CEO transition and settlements announced.BRBR
Q1 20268 Jul 2026 - Net sales and earnings surged, guidance raised, and Premier Protein drove record growth.BRBR
Q3 20248 Jul 2026 - Q2 sales rose 2% but margins and earnings fell sharply amid inflation and inventory charges.BRBR
Q2 20265 May 2026 - All proposals passed with strong support and no shareholder questions were raised.BRBR
AGM 20263 Feb 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay; online access promoted.BRBR
Proxy Filing16 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve pay, with focus on governance and ESG.BRBR
Proxy Filing16 Dec 2025